A synthetic peptide marketed for faster healing of tendons, muscle, ligaments, and the gut. Its reputation rests on consistent animal experiments, but only a handful of small human studies exist, so the benefits remain unproven. There is essentially no human safety data, an unresolved tumor-blood-supply concern, and a supply of frequently contaminated, unapproved products. Investigational; banned in sport. (Full Review)

Protocol

Dose

250–500 µg, 1–2× daily

Common practitioner/community use, not evidence-based; no validated protocol exists.

Route

Subcutaneous injection or oral

Injection often near injury; oral promoted for gut goals, human bioavailability unproven.

Duration

Short courses of several weeks

Split twice-daily dosing common given the under-30-minute half-life; often cycled.

Time to effect

Musculoskeletal healing

One to several weeks

Anecdotal; cannot be separated from natural recovery, as no controlled human trials exist.

Benefits

Low: Musculoskeletal soft-tissue healing; gastrointestinal protection and ulcer/gut healing

Speculative: Joint pain relief; nerve and spinal cord recovery; vascular, cardiac, and systemic cytoprotection; general recovery, inflammation, and longevity support

Contraindications

Anti-angiogenic cancer therapies (e.g., bevacizumab)

Active or prior cancer, or strong family cancer history

Pregnancy or breastfeeding

Competitive athletes subject to anti-doping rules (WADA-prohibited at all times)

Military service members

Key Interactions

Anticoagulants and antiplatelet drugs (e.g., warfarin, apixaban, clopidogrel)

High-dose NSAIDs (e.g., ibuprofen, naproxen) or aspirin

Supplements affecting bleeding or angiogenesis (e.g., high-dose fish oil, vitamin E, ginkgo)

Other recovery peptides (e.g., TB-500/thymosin beta-4)

Risk & Side Effects

High: Unregulated, contaminated, or mislabeled product; absence of human safety data

Low: Theoretical promotion of tumor growth

Speculative: Injection-site and administration reactions; unknown effects of broad systemic signaling

Monitoring

Marker	Target	Why
CBC	Within reference range, no unexplained shifts	Screen for infection or hematologic change
CMP	Within reference range	Liver and kidney function
Liver enzymes (ALT, AST)	Low-normal (often <25 U/L)	Detect hepatic stress from compound or contaminants
eGFR / creatinine	eGFR >90 mL/min/1.73m²	Confirm renal clearance capacity
hs-CRP	<1.0 mg/L	Detect systemic inflammation, including from endotoxin-contaminated product

Cadence: Baseline, then around 4–8 weeks during a course, and again if use is repeated or extended.

Qualitative Assessment

Injury-specific function (pain, range of motion, load tolerance, return-to-activity progress)
Subjective recovery speed and perceived soreness
Energy levels and general well-being
Any new symptoms — injection-site reactions, fevers (possible endotoxin sign), or unexplained changes
Age- and risk-appropriate cancer screening up to date and unremarkable

BPC-157 for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment